CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Ateganosine (THIO, 6-thio-2'-deoxyguanosine), a first-in-class telomere-targeting therapy under development by MAIA Biotechnology (NYSE American: MAIA), appears to be gaining increasing attention in the oncology community as emerging clinical results continue to surpass expectations in advanced non-small cell lung cancer (NSCLC). With the therapy’s Phase 2 trial ongoing and a pivotal Phase 3 program initiated this week, ateganosine is being closely watched as one o ...

TORONTO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Galway Metals Inc. (TSXV: GWM) (“Galway” or the “Corporation”) is pleased to announce that it has closed its previously announced non-brokered private placement (the “Private Placement”) consisting of 855,370 units of the Corporation (“Units”) at a price of $0.54 per Unit for aggregate gross proceeds to the Corporation of $461,899.80. Each Unit consists of one common share of the Corporation, and one half of one transferable common share purchase warrant (a “Warran ...

Core Insights - AB Science announced a new publication on MedRxiv detailing the clinical benefits of masitinib for amyotrophic lateral sclerosis (ALS) patients before any complete loss of function [2][3] Group 1: Study Findings - The post-hoc subgroup analysis from the phase 2b/3 AB10015 study shows significant improvement in functional decline measured by the ALSFRS-R score, with a 4.04-point difference favoring masitinib over placebo (p=0.0065) [4][5] - A relative benefit of +20.2% on the CAFS score was observed compared to placebo (p=0.0290), surpassing the +13.8% benefit seen in the primary analysis [5] - Median progression-free survival (PFS) was extended by 9 months (p=0.0057) and median overall survival (OS) increased by 12 months (p=0.0192) compared to placebo, both improvements being more pronounced than those in the primary analysis [5] Group 2: Safety and Patient Population - Safety outcomes improved, with a reduction in serious adverse events from 27.6% to 22.6% in masitinib-treated patients [5] - The subgroup analyzed included patients with a score of at least 1 on all ALSFRS-R items at baseline, representing approximately 85% of the primary analysis population [3][5] Group 3: Future Studies - The findings from this analysis will inform the design of the confirmatory study AB23005, which targets patients prior to any complete loss of function to optimize the benefit-risk balance [2][3] - Study AB23005 is a prospective, multicenter, randomized, double-blind, placebo-controlled trial involving 408 ALS patients, aiming to confirm the efficacy and safety of masitinib [7][8]

Core Points - BPCE and Generali have decided to end negotiations regarding the establishment of a joint venture in asset management, concluding that the conditions for a final agreement are not currently present [2][1] - Both companies reaffirm their commitment to developing a competitive financial industry in Europe, contributing to the region's economic success [2] Company Overview: BPCE - Groupe BPCE is the second-largest banking group in France and the fourth-largest in the euro zone by capital, serving 35 million customers globally through its retail banking and insurance operations [3] - The group employs 100,000 staff and operates through major networks including Banque Populaire and Caisse d'Epargne, as well as Natixis Investment Managers for asset and wealth management [3] - BPCE's financial strength is recognized by four credit rating agencies, with ratings including A1 from Moody's and A+ from both Standard & Poor's and Fitch [3] Company Overview: Generali - Generali is one of the largest integrated insurance and asset management groups globally, with a total premium income of €95.2 billion and €863 billion in assets under management (AUM) as of 2024 [4] - The company operates in over 50 countries, employing around 87,000 staff and serving 71 million customers, with a strong presence in Europe and growing markets in Asia and Latin America [4] - Generali's strategy focuses on customer commitment through innovative solutions and sustainability, aiming to create value for stakeholders and build a more resilient society [4]

Voltalia awarded 68 megawatts in Italy through FERX auction Voltalia (Euronext Paris, ISIN code: FR0011995588), an international player in renewable energies, announces securing 20 years tariff for 68 megawatts solar projects in Italy Voltalia Italy established in Milan since 2019 and in Agrigento since 2022, with a solar and storage pipeline of more than 500 megawatts, takes a new step with four projects selected in FERX tariff auction, strengthening its role in the development of renewable energy in Ital ...

PRESS RELEASE Arcueil, December 11, 2025 Alejandro Garcia Mella appointed Chief Executive Officer at Clicars, Aramis Group's Spanish entity Aramis Group announces the appointment of Alejandro Garcia Mella as Chief Executive Officer at Clicars. He succeeds José Carlos del Valle, who is now pursuing a new professional project. With over 15 years of experience within the organization, Alejandro Garcia has contributed decisively to the Group's growth across all its geographies. His proven expertise, in-depth k ...

Rexel: Statement relating to the total number of shares and voting rights pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Rules of the French Autorité des marchés financiers DateNumber of sharesNumber of voting rights2025-11-30299,036,619Theoretical number of voting rights(1): 299,036,619Exercisable number of voting rights(2): 293,849,850 (1) Number of voting rights including treasury shares deprived from voting rights.(2) Number of voting rights excluding trea ...

Kering - Press release - IFRS 5 - 11 12 2025 - EN PRESS RELEASEDecember 11, 2025 FINANCIAL INFORMATION REGARDING THE RECLASSIFICATIONOF KERING BEAUTÉ IN ACCORDANCE WITH IFRS 5 Following the agreement with L’Oréal for the sale of Kering Beauté, expected to close in the first half of 2026, Kering Beauté’s activity (for which Kering has exercised its right to sell to L’Oréal) will be reclassified as discontinued operations in the consolidated financial statements as of December 31, 2025, under IFRS 5. Accordin ...

Core Insights - SPIE, a European leader in multi-technical services, has signed an agreement to acquire 93% of Artemys, a French expert in digital transformation [1][4] - Artemys, founded in 1989, generated approximately €82 million in revenue in 2024 and has a diversified client portfolio across various sectors [2][4] - The acquisition will enhance SPIE's capabilities in cloud, big data, and cybersecurity, particularly for large accounts and mid-sized companies in France [3][4] Company Overview - SPIE achieved consolidated revenues of €9.9 billion and consolidated EBITA of €712 million in 2024, with a workforce of 55,000 employees [5] - Artemys employs 420 people across 7 offices and specializes in the design, management, and transformation of information systems [2][4] Strategic Implications - The acquisition is expected to strengthen SPIE's expertise in digital transformation and improve service offerings in strategic areas such as cloud and cybersecurity [3][4] - The transaction is anticipated to be finalized by early 2026, pending approval from competition authorities [4]

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announced today that its subsidiary Serensia by Quadient has received final accreditation from the French Tax Authority (DGFiP) as a registered e-invoicing platform. This certification confirms that all requirements identified during the review phase have been fully met and that the platform is now approved and operational immediately. This achievement positions Serensia by Quadient among the ...